Highlights

  • Actinogen Medical shares rose 2.63% to AUD 0.039 on 28 May 2026, after the company received positive scientific advice from the European Medicines Agency (EMA).
  • EMA guidance aligned closely with earlier feedback received from the US FDA.
  • The EMA supported the design of one additional pivotal phase 3 Alzheimer’s trial.
  • Actinogen said the update provides a clearer pathway toward Marketing approval in Europe and the US.
  • Final topline results from the XanaMIA Alzheimer’s trial are expected in November 2026.
  • The company’s lead drug candidate, Xanamem, targets elevated cortisol levels in the brain.

Actinogen Medical Ltd (ASX:ACW) shares rose during morning trade on 28 May 2026 after the biotechnology company announced favourable feedback from the European Medicines Agency (EMA) regarding its Alzheimer’s disease development program for Xanamem.

The stock traded at AUD 0.039, up 2.63% for the session, while the company’s shares have also climbed approximately 95% over the past year. Investor attention appeared to centre on the regulatory clarity provided by the EMA, particularly as the advice closely aligned with earlier guidance from the US Food and Drug Administration (FDA).

The latest update is considered important for Actinogen as it continues advancing Xanamem through late-stage development for Alzheimer’s disease, one of the largest and most closely watched areas within the global biotechnology sector.

EMA Feedback Supports Regulatory Pathway

Actinogen confirmed it had received the written outcome from its scheduled scientific advice meeting with the EMA concerning the future development pathway for Xanamem in Alzheimer’s disease.

According to the company, discussions with the European regulator resulted in a common understanding regarding the key requirements needed for a future marketing application.

Importantly, the EMA agreed with the suitability of the regulatory starting materials planned for the commercial Manufacturing process of Xanamem’s drug substance. The agency also aligned with the company’s proposal for one additional pivotal phase 3 trial using a 10 mg dose of Xanamem compared with placebo following positive results from the ongoing XanaMIA study.

The EMA additionally indicated a preference for broader inclusion criteria in the future study to include patients with moderate Alzheimer’s disease severity.

Actinogen stated that the regulator also accepted the proposed makeup of the planned safety database, which the company said aligns with both EMA and FDA requirements.

Alongside the pivotal study, the EMA recommended a relatively limited number of ancillary clinical pharmacology and non-clinical studies to further evaluate safety, metabolism and excretion pathways associated with Xanamem.

Alignment Between EMA and FDA Viewed Positively

One of the more significant aspects of the announcement was the consistency between European and US regulatory feedback.

Actinogen noted that the EMA guidance closely matched advice previously received from the FDA’s Neurology-I Division. The company said this now provides a clearer development and approval framework across the two largest pharmaceutical markets globally.

Management believes alignment between both regulators may also support future discussions with potential commercialisation and development partners.

For biotechnology companies developing late-stage therapies, differing regulatory expectations between major agencies can often create delays, additional studies or higher development costs. Investors appeared encouraged that the EMA and FDA feedback broadly supported the same development approach for Xanamem.

The company suggested this clarity may help streamline future trial planning and regulatory preparation as development progresses.

Focus Turns Toward XanaMIA Trial Results

The latest regulatory update also shifts further market attention toward the upcoming topline results from the ongoing XanaMIA Phase 2b/3 Alzheimer’s disease trial.

Actinogen expects final results from the study in November 2026.

The XanaMIA trial is evaluating Xanamem in 247 patients with mild to moderate Alzheimer’s disease and progressive symptoms. Participants are receiving either a 10 mg daily dose of Xanamem or placebo over a 36-week treatment period.

The primary endpoint is the Clinical Dementia Rating scale – Sum of Boxes (CDR-SB), which is widely used internationally to assess Alzheimer’s disease progression.

The trial is being conducted across Australia and the United States and has already completed recruitment. According to the company, the study has also passed an independent Data Monitoring Committee review assessing both safety and efficacy futility.

Actinogen stated that positive results from XanaMIA could support commencement of a second pivotal study in patients with mild to moderate Alzheimer’s disease during the middle of next year.

Chief Medical Officer Dr Dana Hilt said the company is looking forward to what it described as potentially important trial results later this year, particularly regarding the ability of cortisol control in the brain to slow Alzheimer’s progression.

Understanding Xanamem and Its Mechanism

Xanamem, also known as emestedastat, is Actinogen’s lead investigational therapy and is designed to control elevated cortisol levels inside the brain.

Cortisol is commonly referred to as the “stress hormone,” and chronically elevated levels have been associated with cognitive decline, damage to brain cells and progression of neurological conditions such as Alzheimer’s disease.

Unlike some alternative approaches, Xanamem works by inhibiting the enzyme 11β-HSD1, which plays a role in cortisol production inside brain cells, without affecting normal cortisol production from the adrenal glands.

The company describes Xanamem as a once-daily oral therapy designed to achieve cortisol control in areas of the brain associated with memory and cognition, including the hippocampus and frontal cortex.

Actinogen stated that more than 500 volunteers and patients have been studied across eight Clinical Trials involving Xanamem.

The company also highlighted previous findings from its XanaCIDD depression trial, where the therapy demonstrated clinically and statistically significant benefits on depression symptoms using measures such as the MADRS scale and PGI-S assessments.

While cognition improved in both treatment and placebo groups in the depression study, management said the results still provided additional support for the broader cortisol-control mechanism underpinning Xanamem.

Why Investors Reacted Positively

The market response on Thursday appeared linked to several factors within the announcement.

Firstly, investors often place considerable value on regulatory clarity, particularly in biotechnology where approval pathways can significantly affect timelines, development costs and commercial potential.

Secondly, the alignment between EMA and FDA guidance may reduce uncertainty surrounding future development requirements for Xanamem.

The company’s confirmation that only one additional pivotal phase 3 trial may be required following positive XanaMIA results also appeared to support investor sentiment.

In addition, the announcement arrives ahead of a potentially significant catalyst later this year, with final XanaMIA results expected in November.

Although Xanamem remains an investigational therapy and has not received approval outside clinical studies, the latest regulatory progress suggests the company is continuing to advance its Alzheimer’s disease program in line with planned timelines.

About Actinogen Medical

Actinogen Medical is an ASX-listed biotechnology company focused on therapies targeting neurological and neuropsychiatric conditions linked to dysregulated cortisol levels in the brain.

The company’s research is based on evidence associating elevated cortisol with impaired cognitive function, brain cell damage and long-term neurological decline.

Beyond Alzheimer’s disease, Actinogen has also explored Xanamem’s potential application in cognitive Impairment associated with depression and may evaluate additional neurological or psychiatric indications in the future, including Fragile X Syndrome.

The company believes reducing cortisol levels within brain cells could provide therapeutic benefits across several conditions involving cognitive dysfunction, behavioural abnormalities and neuropsychological impairment.

What Investors May Watch Next

Following the EMA update, investor focus is likely to remain on several upcoming milestones.

The most immediate catalyst remains the release of final XanaMIA Phase 2b/3 trial results expected in November 2026.

Beyond that, investors may watch for additional updates regarding Partnership discussions, commencement timelines for a second pivotal study and further interactions with global regulators.

The company’s ability to translate regulatory guidance into successful late-stage clinical outcomes may remain central to market sentiment over the coming months.